Quantcast
Channel: CancerConnect News » General Bone Cancer
Browsing latest articles
Browse All 12 View Live

Heart Dysfunction Continues Long After Treatment with Adriamycin®

Heart Dysfunction Continues Long After Treatment with Adriamycin® According to results published in the Annals of Oncology, childhood cancer survivors with bone cancer who were treated with Adriamycin®...

View Article



Shortened Interval Between Chemotherapy Cycles Does Not Improve Survival with...

Shortened Interval Between Chemotherapy Cycles Does Not Improve Survival with Osteosarcoma According to the results of a study published in the Journal of the National Cancer Institute, osteosarcoma...

View Article

Denosumab Reduces the Risk of Bone Fractures

Denosumab Reduces the Risk of Bone Fractures According to the results of a Phase III clinical trial, treatment with denosumab significantly reduces the risk of vertebral and hip fractures among...

View Article

Denosumab Active Against Giant Cell Tumor of Bone

In a Phase II clinical trial, denosumab produced high rates of tumor response among patients with recurrent or unresectable giant cell tumors of bone. These results were published in Lancet Oncology....

View Article

Stay on Top of Your Family History of Cancer

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time,...

View Article


Xgeva Delays Onset of Bone Metastases

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011...

View Article

Aspirin Continues to Look Promising for Cancer Prevention

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A...

View Article

Xgeva Reduces Giant-cell Tumor of the Bone

Xgeva® (denosumab) significantly reduced or eliminated tumor giant cells in patients with giant-cell tumor of the bone and also increased new bone formation, according to the results of a phase II...

View Article


Xgeva Approved for Treatment of Giant Cell Tumor of the Bone

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant...

View Article


Xgeva Safe and Effective for Giant Cell Tumor of the Bone

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant...

View Article
Browsing latest articles
Browse All 12 View Live




Latest Images